Jelle Verhoeven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jelle Verhoeven has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Adinda Baten
Department of Radiotherapy Oncology, KU Leuven—University of Leuven, University Hospital Leuven, Leuven, Belgium
2 shared publications - Françoise Derouane
General Medical Oncology Unit, Department of Oncology, UZ Leuven, Leuven, Belgium
2 shared publications - Maxime Van Houdt
Department of Gynaecological Oncology/Multidisciplinary Breast Center, UZ Leuven-University Hospitals Leuven-Campus Gasthuisberg, Leuven, Belgium
2 shared publications - A. Heather Eliassen
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
1 shared publication - ABCTB Investigators
Australian Breast Cancer Tissue Bank, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW 2145, Australia
1 shared publication Adhithya Narayanan Srinivasan
Cell Death Research and Therapy Laboratory, Center for Cancer Biology, VIB, Leuven, Belgium
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Elsevier in SSRN Electronic Journal
Tamoxifen use increases endometrial cancer risk in premenopausal breast cancer patients
Tamoxifen increases the risk of endometrial cancer (ECa) when treating breast cancer (BC)in postmenopausal women, but the impact in premenopausal women is not well established. A retrospective study in South-Korea suggested that premenopausal BC patients were 3.77 times more likely to develop ECa when treated with tamoxifen. We aimed to validate these results in a large-scale nationwide study in Belgium.We conducted a retrospective cohort study in women, aged 18–53, diagnosed with non-metastatic BC in Belgium between 2008 and 2020. Patients treated with tamoxifen were compared to those not treated with tamoxifen by baseline characteristics and diagnosis of ECa. The primary endpoint was time to ECa diagnosis. A Cox proportional hazards model assessed the primary endpoint, with treatment group as the main variable and patient/tumor characteristics as covariates.We included 23 289 patients (60%; median age 47 years) in the tamoxifen group and 15 568 patients (40%; median age 47 years) in the non-tamoxifen group. Tamoxifen users were more likely to have low-grade and lobular tumors, and less likely to receive (neo-)adjuvant or targeted (chemo)therapy. 96 ECa events occurred in the tamoxifen group (0.41%) and 27 in the non-tamoxifen group (0.17%). This translated to 0.51% and 0.22% of survivors, respectively which was a statistically significant difference (HR 2.05, CI: 1.34-3.15). After adjusting for potential confounders—diabetes, cardiovascular profile, tumor grade, pT, pN, chemotherapy, and targeted therapy—the risk remained significantly elevated in the tamoxifen group (adjusted HR 1.93, CI: 1.14-3.28; p = 0.0141).
- 14 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTamoxifen use increases endometrial cancer risk in premenopausal breast cancer patients
Tamoxifen increases the risk of endometrial cancer (ECa) when treating breast cancer (BC)in postmenopausal women, but the impact in premenopausal women is not well established. A retrospective study in South-Korea suggested that premenopausal BC patients were 3.77 times more likely to develop ECa when treated with tamoxifen. We aimed to validate these results in a large-scale nationwide study in Belgium.We conducted a retrospective cohort study in women, aged 18–53, diagnosed with non-metastatic BC in Belgium between 2008 and 2020. Patients treated with tamoxifen were compared to those not treated with tamoxifen by baseline characteristics and diagnosis of ECa. The primary endpoint was time to ECa diagnosis. A Cox proportional hazards model assessed the primary endpoint, with treatment group as the main variable and patient/tumor characteristics as covariates.We included 23 289 patients (60%; median age 47 years) in the tamoxifen group and 15 568 patients (40%; median age 47 years) in the non-tamoxifen group. Tamoxifen users were more likely to have low-grade and lobular tumors, and less likely to receive (neo-)adjuvant or targeted (chemo)therapy. 96 ECa events occurred in the tamoxifen group (0.41%) and 27 in the non-tamoxifen group (0.17%). This translated to 0.51% and 0.22% of survivors, respectively which was a statistically significant difference (HR 2.05, CI: 1.34-3.15). After adjusting for potential confounders—diabetes, cardiovascular profile, tumor grade, pT, pN, chemotherapy, and targeted therapy—the risk remained significantly elevated in the tamoxifen group (adjusted HR 1.93, CI: 1.14-3.28; p = 0.0141).
- Open Access
Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women
Background: Breast cancer polygenic risk scores (PRS) and traditional risk models (e.g., the Gail model [Gail]) are known to contribute largely independent information, but it is unclear how the overlap varies by ancestry, age, disease type (invasive breast cancer, DCIS), and risk threshold. Methods: In a retrospective case–control study, we evaluated risk prediction performance in 180,398 women (161,849 of European ancestry; 18,549 of Asian ancestry). Odds ratios (ORs) from logistic regression models and the area under the receiver operating characteristic curve (AUC) were estimated. Results: PRS for invasive disease showed a stronger association in younger (p < 0.001) and Gail (p < 0.001) in Europeans, whereas in Asians, age interaction was observed only for Gail (invasive: p < 0.001; DCIS: p = 0.002). PRS identified more high-risk individuals than Gail in Asian populations, especially ≥50 years, while Gail identified more in Europeans. Overlap between PRS, Gail, and family history was limited at higher thresholds. Calibration analysis, comparing empirical and model-based ROC curves, showed divergence for both PRS and Gail (p < 0.001), which indicates miscalibration. In Europeans, family history and prior biopsies drove Gail discrimination. In younger Asians, age at first live birth was influential. Conclusions: PRS adds value to risk stratification beyond traditional tools, especially in younger women and Asian ancestry populations.
Open AccessThreshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women
Background: Breast cancer polygenic risk scores (PRS) and traditional risk models (e.g., the Gail model [Gail]) are known to contribute largely independent information, but it is unclear how the overlap varies by ancestry, age, disease type (invasive breast cancer, DCIS), and risk threshold. Methods: In a retrospective case–control study, we evaluated risk prediction performance in 180,398 women (161,849 of European ancestry; 18,549 of Asian ancestry). Odds ratios (ORs) from logistic regression models and the area under the receiver operating characteristic curve (AUC) were estimated. Results: PRS for invasive disease showed a stronger association in younger (p < 0.001) and Gail (p < 0.001) in Europeans, whereas in Asians, age interaction was observed only for Gail (invasive: p < 0.001; DCIS: p = 0.002). PRS identified more high-risk individuals than Gail in Asian populations, especially ≥50 years, while Gail identified more in Europeans. Overlap between PRS, Gail, and family history was limited at higher thresholds. Calibration analysis, comparing empirical and model-based ROC curves, showed divergence for both PRS and Gail (p < 0.001), which indicates miscalibration. In Europeans, family history and prior biopsies drove Gail discrimination. In younger Asians, age at first live birth was influential. Conclusions: PRS adds value to risk stratification beyond traditional tools, especially in younger women and Asian ancestry populations.
- 20 February 2025
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (4) , 368-382
Radiation-induced heart disease in breast cancer patients: a narrative review of epidemiology, risk factors, radiotherapy parameters, and prevention
Background Breast cancer is the most prevalent cancer in women worldwide; nevertheless, the prognosis is good, with a 5-year overall survival of 80–90%. Therefore, it becomes crucial to strive for high quality of life after cure by minimizing treatment-related toxicity. One such concern is radiation-induced heart disease, which remains a significant focus of ongoing investigations. Purpose The aim of this review is to summarize current knowledge on radiation-induced heart disease in breast cancer patients by giving an overview of its epidemiology, risk factors, radiation parameters related to its development, solutions in radiation practice, and prevention. The goal is to raise awareness and maximize prevention of radiation-induced heart disease. Methods The PubMed database was screened for articles published between January 2013 and November 2023 related to the keywords , , , and . Moreover, by screening the literature lists of these publications, additional articles were added. Results Ninety-four relevant papers remained for final review. Conclusion Radiation-induced heart disease is a rare complication after breast cancer radiotherapy and represents a clinical spectrum of various cardiovascular conditions. Several heart-sparing techniques have been developed, and more attention has been paid to early diagnosis and prevention of radiation-induced heart disease. However, further research remains important to refine radiotherapy techniques and deepen our understanding for improved prevention and treatment of this condition in the future. This clinical review summarizes the existing evidence and literature on radiation-induced heart disease following modern breast cancer radiotherapy, offering clinical guidance for physicians.
- 20 February 2025
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (4) , 368-382
Radiation-induced heart disease in breast cancer patients: a narrative review of epidemiology, risk factors, radiotherapy parameters, and prevention
Background Breast cancer is the most prevalent cancer in women worldwide; nevertheless, the prognosis is good, with a 5-year overall survival of 80–90%. Therefore, it becomes crucial to strive for high quality of life after cure by minimizing treatment-related toxicity. One such concern is radiation-induced heart disease, which remains a significant focus of ongoing investigations. Purpose The aim of this review is to summarize current knowledge on radiation-induced heart disease in breast cancer patients by giving an overview of its epidemiology, risk factors, radiation parameters related to its development, solutions in radiation practice, and prevention. The goal is to raise awareness and maximize prevention of radiation-induced heart disease. Methods The PubMed database was screened for articles published between January 2013 and November 2023 related to the keywords , , , and . Moreover, by screening the literature lists of these publications, additional articles were added. Results Ninety-four relevant papers remained for final review. Conclusion Radiation-induced heart disease is a rare complication after breast cancer radiotherapy and represents a clinical spectrum of various cardiovascular conditions. Several heart-sparing techniques have been developed, and more attention has been paid to early diagnosis and prevention of radiation-induced heart disease. However, further research remains important to refine radiotherapy techniques and deepen our understanding for improved prevention and treatment of this condition in the future. This clinical review summarizes the existing evidence and literature on radiation-induced heart disease following modern breast cancer radiotherapy, offering clinical guidance for physicians.
- Open Access
- 27 November 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (12) , e18028
Tumor endothelial cell autophagy is a key vascular‐immune checkpoint in melanoma
Tumor endothelial cells (TECs) actively repress inflammatory responses and maintain an immune‐excluded tumor phenotype. However, the molecular mechanisms that sustain TEC‐mediated immunosuppression remain largely elusive. Here, we show that autophagy ablation in TECs boosts antitumor immunity by supporting infiltration and effector function of T‐cells, thereby restricting melanoma growth. In melanoma‐bearing mice, loss of TEC autophagy leads to the transcriptional expression of an immunostimulatory/inflammatory TEC phenotype driven by heightened NF‐kB and STING signaling. In line, single‐cell transcriptomic datasets from melanoma patients disclose an enriched Inflammatory High /Autophagy Low TEC phenotype in correlation with clinical responses to immunotherapy, and responders exhibit an increased presence of inflamed vessels interfacing with infiltrating CD8 + T‐cells. Mechanistically, STING‐dependent immunity in TECs is not critical for the immunomodulatory effects of autophagy ablation, since NF‐kB‐driven inflammation remains functional in STING/ATG5 double knockout TECs. Hence, our study identifies autophagy as a principal tumor vascular anti‐inflammatory mechanism dampening melanoma antitumor immunity.
- 27 November 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (12) , e18028
Open AccessTumor endothelial cell autophagy is a key vascular‐immune checkpoint in melanoma
Tumor endothelial cells (TECs) actively repress inflammatory responses and maintain an immune‐excluded tumor phenotype. However, the molecular mechanisms that sustain TEC‐mediated immunosuppression remain largely elusive. Here, we show that autophagy ablation in TECs boosts antitumor immunity by supporting infiltration and effector function of T‐cells, thereby restricting melanoma growth. In melanoma‐bearing mice, loss of TEC autophagy leads to the transcriptional expression of an immunostimulatory/inflammatory TEC phenotype driven by heightened NF‐kB and STING signaling. In line, single‐cell transcriptomic datasets from melanoma patients disclose an enriched Inflammatory High /Autophagy Low TEC phenotype in correlation with clinical responses to immunotherapy, and responders exhibit an increased presence of inflamed vessels interfacing with infiltrating CD8 + T‐cells. Mechanistically, STING‐dependent immunity in TECs is not critical for the immunomodulatory effects of autophagy ablation, since NF‐kB‐driven inflammation remains functional in STING/ATG5 double knockout TECs. Hence, our study identifies autophagy as a principal tumor vascular anti‐inflammatory mechanism dampening melanoma antitumor immunity.